Loading organizations...
§ Private Profile · Houston, TX, USA
Developing orally delivered small molecule inhibitors for various diseases.
Tvardi Therapeutics has raised $88.0M across 3 funding rounds.
Tvardi Therapeutics has raised $88.0M in total across 3 funding rounds.
Tvardi Therapeutics has raised $88.0M across 3 funding rounds. Most recently, it raised $74.0M Series B in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 23, 2021 | $74M Series B | 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie Mcnab | Sporos Bioventures | Announced |
| Jul 26, 2020 | $5M Grant | National Cancer Institute | — | Announced |
| Sep 24, 2018 | $9M Series A | — | — | Announced |
Tvardi Therapeutics has raised $88.0M in total across 3 funding rounds.
Tvardi Therapeutics's investors include 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie McNab, Sporos Bioventures, National Cancer Institute.